Study
Opening the study…
Study
Opening the study…
There’s a newer version. You’re reading v1, and its author has corrected it since. Claims that didn’t change keep their verification.
Read v2, the newestWhat the study cites, as its author lists it: published work, and what it builds on from this ledger, such as claims, ideas, and registered plans.
Registered plan
prereg:14d63d84…7012
Mapping the effectiveness and risks of GLP-1 receptor agonists
Xie, Y., Choi, T., Al-Aly, Z. (2025)
Estimation of a common effect parameter from sparse follow-up data
Greenland, S., Robins, J. M. (1985)
Controlling the false discovery rate: a practical and powerful approach to multiple testing
Benjamini, Y., Hochberg, Y. (1995)
Meta-analysis in clinical trials
DerSimonian, R., Laird, N. (1986)
Beta blockade during and after myocardial infarction: an overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., Sleight, P. (1985)
Compared with, not cited as support
Han, S., Liu, Y., Xing, B., Yang, Y., Liu, Z. (2025)
Compared with, not cited as support
GLP-1 receptor agonists and noncardiometabolic outcomes: an umbrella review of meta-analyses
Yang, K., Liu, C., Guo, Q., Li, Y. (2026)
Compared with, not cited as support
Yu, M., Wang, R., Pei, L., Zhang, X., Wei, J. (2023)
Compared with, not cited as support
The effect of semaglutide on mortality and COVID-19-related deaths
Scirica, B. M., Lincoff, A. M., Lingvay, I., Bogdanski, P., Buscemi, S. (2024)
Compared with, not cited as support
Tang, E., Ravaud, P., Riveros, C., Perrodeau, E., Dechartres, A. (2015)
Compared with, not cited as support
Wen, J., Nadora, D., Bernstein, E., How-Volkman, C., Truong, A. (2025)
Compared with, not cited as support
GLP-1 receptor agonists and the risk of thyroid cancer
Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R. (2023)